Resumo

SALDARRIAGA-RIUERA, Lina María  e  LOPEZ-VILLEGAS, Víctor Jaime. Janus kinase inhibitors as a therapeutic option in rheumatoid arthritis and associated interstitial lung disease. Report of four cases. Rev.Colomb.Reumatol. [online]. 2019, vol.26, n.2, pp.137-139.  Epub 20-Maio-2020. ISSN 0121-8123.  https://doi.org/10.1016/j.rcreu.2018.02.002.

Rheumatoid arthritis (RA) is a systemic disease for which multiple therapeutic options have been developed in the last decades. Based on the information available in the literature, the use of biological therapy in patients with diffuse lung disease is not recommended because these medications can exacerbate the lung disease. A newer drug is the Janus kinase enzyme inhibitor, which can be used as monotherapy or in combination in patients with moderate to high activity RA, in whom the use of synthetic or biological DMARDs is contraindicated, as well as in patients with therapeutic failure. However, the pulmonary safety of the drug has not been evaluated in clinical trials and the information available is limited. This article discusses the treatment, follow-up, and outcomes of the use of tofacitinib in a series of 4 patients with lung disease secondary to RA.

Palavras-chave : Rheumatoid arthritis; Interstitial lung diseases; Janus kinase inhibitors; Biological therapy.

        · resumo em Espanhol     · texto em Espanhol | Inglês     · Inglês ( pdf ) | Espanhol ( pdf )